Biogen reported $9.94B of revenue over the trailing twelve months, +1.2% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $9.94B (to Q1 2026). Net Income: $1.37B, trailing twelve months to Q1 2026. Free Cash Flow: $2.42B, trailing twelve months to Q1 2026. Op Margin: 16%, trailing twelve months to Q1 2026.

BIIBBiogen

HealthcareUSD

$221.12

$127.7552 weeks$221.50

BIIB as reported

Biogen reported $9.94B of revenue over the trailing twelve months, +1.2% on the year before. 11 reported series are charted on this page, each one as filed.

$9.94B

Revenue, trailing twelve months · to Q1 2026 · +1.2% against the twelve months before

Net Income: $1.37B
Net Income · −7.3% year on year · trailing twelve months to Q1 2026
Free Cash Flow: $2.42B
Free Cash Flow · −0.57% year on year · trailing twelve months to Q1 2026
Op Margin: 16%
Op Margin · trailing twelve months to Q1 2026

Every series Ryufin has for BIIB, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$9.94B	+1.2%	Q1 2026
Net Income	$1.37B	−7.3%	Q1 2026
EPS	$9.30	−8.2%	Q1 2026
Gross Margin	76%	n/a	Q1 2026
Op Margin	16%	n/a	Q1 2026
Net Margin	13%	n/a	Q1 2026
ROE	8.0%	n/a	Q1 2026
ROA	5.0%	n/a	Q1 2026
ROIC	6.5%	n/a	Q1 2026
Free Cash Flow	$2.42B	−0.57%	Q1 2026
P/E	23.8	n/a	today